Chang, Sam S <br/><br/>
Re: Phase III, Double-Blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-Line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.  [electronic resource] 

 -  The Journal of urology  04 2018 
 - 891-892 p.  digital 
<br/><br/> Publication Type: Journal Article; Comment 
<br/><br/><label>ISSN: </label>1527-3792 
<br/><br/><label>Standard No.: </label>10.1016/j.juro.2018.01.006  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Double-Blind Method<br/>Humans<br/>Lapatinib<br/>Receptor, ErbB-2<br/>Receptors, Estrogen<br/>Urinary Bladder Neoplasms